Mechanism of Action: Bradykinin B2 Receptor Antagonists
✉ Email this page to a colleague
Drugs with Mechanism of Action: Bradykinin B2 Receptor Antagonists
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Kabi Usa | ICATIBANT ACETATE | icatibant acetate | INJECTABLE;SUBCUTANEOUS | 208317-001 | Jun 18, 2020 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Cipla | ICATIBANT ACETATE | icatibant acetate | INJECTABLE;SUBCUTANEOUS | 212446-001 | Jul 13, 2020 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Teva Pharms Usa | ICATIBANT ACETATE | icatibant acetate | INJECTABLE;SUBCUTANEOUS | 210118-001 | Jul 15, 2019 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Wilshire Pharms Inc | ICATIBANT ACETATE | icatibant acetate | INJECTABLE;SUBCUTANEOUS | 211501-001 | Sep 1, 2020 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Jiangsu Hansoh Pharm | ICATIBANT ACETATE | icatibant acetate | INJECTABLE;SUBCUTANEOUS | 211021-001 | Mar 9, 2020 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Eugia Pharma | ICATIBANT ACETATE | icatibant acetate | INJECTABLE;SUBCUTANEOUS | 213521-001 | Aug 14, 2023 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Nang Kuang Pharm Co | ICATIBANT ACETATE | icatibant acetate | INJECTABLE;SUBCUTANEOUS | 212081-001 | Dec 16, 2020 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
